Deals Of The Week: Upsher-Smith/Proximagen, Novo Nordisk/JDRF, Newron/NeuroNova
Executive Summary
With BIO 2012 taking place June 17-21, the entire health care world awaits the Supreme Court’s ruling on health care reform. In the pharma world, companies are strategizing against all the possible outcomes.
You may also be interested in...
Roche’s POL7080 Polyphor Pact Signals Re-Entry Into Antibiotics R&D
By choosing Switzerland-based Polyphor’s investigational macrocycle antibiotic POL7080 for development and commercialization, Roche has given notice that it’s back in the antimicrobials space again.
Roche’s POL7080 Polyphor Pact Signals Re-Entry Into Antibiotics R&D
By choosing Switzerland-based Polyphor’s investigational macrocycle antibiotic POL7080 for development and commercialization, Roche has given notice that it’s back in the antimicrobials space again.
Upsher-Smith To Buy U.K. Biotech Partner Proximagen For $347 Million
Proposed acquisition mimics other recent M&A deals, like Sanofi/Genzyme, with inclusion of contingent-value rights pegged to success of two clinical candidates.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: